BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
biospace · 3d ago
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
biospace · 4d ago
6 immunology targets to sustain a mammoth I&I market
Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
biospace · 7d ago
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…
biospace · 25d ago
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
fiercebiotech · 1mo ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 2mo ago
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
biopharma_dive · 3mo ago
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
biopharma_dive · 3mo ago
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 5mo ago

brand

Humira

generic

adalimumab

MOA

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).

indication

Intermediate Uveitis

phase

marketed

approved

2002-12-31

Data sources

openFDA · ClinicalTrials.gov

last refreshed 38m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

adalimumab

🐶 often sniffed alongside

indications

all catalysts(61)

Trials studying adalimumab

News(9)

Report a data issue

comments(0)

adalimumab

🐶 often sniffed alongside

indications

all catalysts(61)

Trials studying adalimumab

News(9)

Report a data issue

comments(0)